

Supplementary Table 1. Comparison of MCI subjects in AV45- A11 study to ADNI LMCI (late MCI subjects in ADNI-1) and EMCI (early subjects MCI from ADNI-GO and ADNI-2).

	AV45-A11 MCI	ADNI EMCI	ADNI LMCI
Age	71.5 (10.1)	71.0 (7.4) <sup>35</sup>	74.7 (7.4) <sup>36</sup>
ADAS-Cog	9.5 (4.5)	7.9 (3.4) <sup>37</sup>	11.5 (4.4) <sup>36</sup>
WMS immediate recall	10.4 (3.7)	10.9 (2.8) <sup>35</sup>	8.7 (4.3) <sup>35</sup>
WMS delayed recall	8.5 (4.5)	8.9 (1.7) <sup>35</sup>	6.1 (4.4) <sup>35</sup>
APOE ε4 (%+)	37.5%	41% <sup>35</sup>	53.3% <sup>36</sup>
Amyloid Positive (%)	37%	43% <sup>38</sup>	62% <sup>38</sup>

AV45- A11 MCI subjects were similar to ADNI EMCI subjects with respect to baseline age, presence of the ApoE ε4 allele, and Wechsler memory scale immediate and delayed recall performance. They were only slightly more impaired on the ADAS-Cog. AV45- A11 MCI subjects were less impaired than ADNI-1 LMCI subjects on Wechsler memory scale immediate and delayed recall tests and the ADAS-Cog. Similarly, AV45- A11 MCI subjects had amyloid positive rates on PET imaging closer to EMCI than to LMCI. Citations are from the reference list in the main text.